Sanpower Reconstructs Dendreon Deal To Drive Better Growth
Executive Summary
Sanpower Group is planning the first Asian launch of Provenge in Hong Kong after acquiring a local cell therapy manufacturing facility, amid the ongoing sale of Dendreon to its public holding company Nanjing Cenbest, the latest deal in the surge of traditional companies breaking into the healthcare sector in China.
You may also be interested in...
Deal Watch: Ionis Out-Licenses Pair Of Generation 2.5 Antisense Candidates
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.